DOXORUBICIN , Rinatabart Sesutecan, PACLITAXEL
GCT1184-03
Phase 3 small_molecule active
Quick answer
DOXORUBICIN , Rinatabart Sesutecan, PACLITAXEL for Endometrial Cancer Advanced, Recurrent, Metastatic, or Primary Unresectable Endometrial Cancer is a Phase 3 program (small_molecule) at Genmab A/S with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Genmab A/S
- Indication
- Endometrial Cancer Advanced, Recurrent, Metastatic, or Primary Unresectable Endometrial Cancer
- Phase
- Phase 3
- Modality
- small_molecule
- Status
- active